Medical/Pharmaceuticals

Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell

— The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI. — The Company is conducting a Phase III registrational study of sac-TMT plus osimertinib as first-line treatment for advanced EGFR-mutant NSCLC (enrollment ...

2026-06-22 14:00 1651

Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders

CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in biotech innovation with groundbreaking drug research,...

2026-06-22 12:37 1654

Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE

*  ATG-106 is a first-in-class CDH6 x CD3 bispecific T cell engager (TCE) in preclinical development for the treatment of solid tumors  *  K2 Therapeutics, established by MPM BioImpact, obtains exclusive global rights to develop and commercialize ATG-106 outside Greater China  *  Antengene r...

2026-06-22 08:30 1798

Murj® Expands Global Footprint with Commercial Launch in Australia and New Zealand

SYDNEY and AUCKLAND, New Zealand, June 22, 2026 /PRNewswire/ -- Murj®, a cardiac device management software company, today announced its official expansion into the Australian market alongside broader availability for New Zealand. Following its exhibition at the recent CSANZ / HRS Advances in Pac...

2026-06-22 07:00 1396

Seoul National University Hospital to Expand Global K-Bio Collaboration at BIO USA 2026

SAN DIEGO and SEOUL, South Korea, June 19, 2026 /PRNewswire/ -- Seoul National University Hospital (SNUH) will take a major step toward expanding K-Bio's global presence and international collaboration at BIO International Convention 2026 (BIO USA), the world's largest biotechnology industry even...

2026-06-19 23:00 3735

INTCO Medical Showcases Medical Consumables, Rehabilitation Medical Equipment and Physical Therapy Solutions at WHX Miami 2026

MIAMI, June 19, 2026 /PRNewswire/ -- INTCO Medical  ("INTCO" or "the Company"), a leading global manufacturer of disposable gloves, is showcasing its medical consumables, rehabilitation medical equipment and physical therapy solutions at World Health Expo (WHX) Mia...

2026-06-19 16:38 4297

Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress

SHANGHAI, June 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, presented two latest clinical study results of its independently developed Nectin-4-targeting ADC 9MW2821 (Bulumtatug Fuvedotin, BFv) in c...

2026-06-18 23:00 3099

Frost & Sullivan Identifies Virtual Healthcare Assistants as a Transformational Force in Healthcare Delivery

New analysis highlights significant growth opportunities in patient- and clinician-facing AI assistants as healthcare organizations seek to improve efficiency, patient engagement, and care outcomes LONDON, June 18, 2026 /PRNewswire/ -- Frost & Sullivan's latest analysis,  Innovations and Growth O...

2026-06-18 21:07 2181

ZEISS announces strategic collaboration with Envision Health Technologies to advance glaucoma care with virtual reality-based function testing

ZEISS Medical Technology and Envision Health Technologies will collaborate to advance the next generation of patient-accessible, software-driven visual function testing while maintaining a science-first approach to glaucoma care. JENA, Germany, June 18, 2026 /PRNewswire/ -- ZEISS Medical Technolo...

2026-06-18 21:00 2175

Navigating Primary Biliary Cholangitis in Singapore: Addressing the Diagnostic Gap and the Next-Generation Therapies

* 90% Female Prevalence: PBC is a critical women's health issue, yet symptoms like crushing fatigue and relentless itching are frequently misdiagnosed as menopause or stress. * 30-Year Innovation Gap: This new class of therapy is the first major breakthrough in three decades for the 40% of pa...

2026-06-18 17:03 3031

WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market

SUZHOU, China, June 18, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Biosafety Testing Center in Suzhou has successfully passed a Good Manufacturing Practice (GMP) inspection by the Europe...

2026-06-18 12:57 4443

AI-Powered Analysis by HistoIndex Reveals Robust Liver Fibrosis Improvement with D&D Pharmatech's Zabopegdutide in Phase 2 MASH Trial

SINGAPORE and SEOUL, South Korea, June 18, 2026 /PRNewswire/ -- HistoIndex, a leader in AI-powered digital pathology solutions for fibrosis assessment, and D&D Pharmatech, today announced positive results from HistoIndex's AI-based quantitative analysis of liver biopsy samples from the Phase 2 cl...

2026-06-18 10:00 3973

ZEISS Medical Technology and Aier Eye Hospital Group Sign Strategic Agreement for 25 VISUMAX 800 Units

JENA, Germany, June 18, 2026 /PRNewswire/ -- ZEISS Medical Technology announced today that the company held a signing ceremony with the Aier Eye Hospital Group, entering into a strategic agreement for the purchase and installation of 25 ZEISS VISUMAX 800 femtosecond lasers across multiple Aier Ey...

2026-06-18 08:49 3210

Tinnitus Quest Builds Momentum with Oxford Research Study, New Funding Call, and Second Tinnitus Hackathon

OXFORD, England, June 18, 2026 /PRNewswire/ -- Tinnitus Quest , an international patient-driven nonprofit dedicated to accelerating research into treatments to silence tinnitus, today announced the launch of a new round of research funding aimed at uncovering bold, in...

2026-06-18 03:55 3369

Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics

CAMBRIDGE, Mass. and HONG KONG, June 17, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced it has achieved the first clinical milestone in its co-development collaboration wit...

2026-06-17 21:00 4396

FiberSense Continuous Glucose Monitoring (CGM) System obtains CE mark as commercial launch preparations begin

Major regulatory milestone paves the way for commercialization and marks first step toward broader CxM biomarker sensing strategy BASEL, Switzerland, June 17, 2026 /PRNewswire/ -- FiberSense AG ("FiberSense") today announced that the FiberSense Continuous Glucose Monitoring (CGM) System has obta...

2026-06-17 17:06 3473

Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat

STOCKHOLM, June 17, 2026 /PRNewswire/ -- Gesynta Pharma AB, a Swedish clinical stage pharmaceutical company focusing on chronic inflammatory diseases, today announced that 50% of the target of 190 patients have been randomized in its Phase 2 clinical proof-of-concept trial (NOVA). The study is ev...

2026-06-17 16:06 3225

Ligufalimab (CD47)-Based Combination Achieves Deep Responses and Survival Benefit in Frontline AML: Phase II Results Presented in Oral Session at EHA 2026

HONG KONG, June 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) were presented as an oral presentation at the 2026 European Hem...

2026-06-17 13:39 3745

RRS® HA Long Lasting awarded Best Injectable in Skin Revitalization at AMWC 2026, reinforcing Skin Tech Pharma Group's leadership in the Skin Builder category

BARCELONA, Spain, June 17, 2026 /PRNewswire/ -- Skin Tech Pharma Group proudly announces that its flagship injectable, RRS® HA LONG LASTING, has been recognized as Best Injectable in the Skin Revitalization category at the AMWC Aesthetic Medicine Awards 2026, one of the most prestigious recogniti...

2026-06-17 08:00 2920

Ruixiang Silicone Releases Platinum-Cured Medical Silicone Tubing for Cardiac, Infusion, and Hemodialysis Device Manufacturers

USP Class VI, ISO 10993 biocompatibility evaluation, and ISO 13485:2016 quality system certification, manufactured at an FDA-registered facility DONGGUAN, China, June 16, 2026 /PRNewswire/ -- Dongguan Ruixiang Precision Silicone Products Co., Ltd. (Ruixiang Silicone) has released a platinum-cured...

2026-06-16 23:10 3586
1 ... 3456789 ... 649